Pinto Venessa L, Guffey Danielle, Loftis Laura, Bembea Melania M, Spinella Philip C, Hanson Sheila J
Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States.
Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, United States.
Front Pediatr. 2021 Sep 28;9:698120. doi: 10.3389/fped.2021.698120. eCollection 2021.
Though commonly used for adjustment of risk, severity of illness and mortality risk prediction scores, based on the first 24 h of intensive care unit (ICU) admission, have not been validated in the pediatric extracorporeal membrane oxygenation (ECMO) population. We aimed to determine the association of Pediatric Index of Mortality 2 (PIM2), Pediatric Risk of Mortality Score III (PRISM III) and Pediatric Logistic Organ Dysfunction (PELOD) scores with mortality in pediatric patients on ECMO. This was a retrospective cohort study of children ≤18 years of age included in the Pediatric ECMO Outcomes Registry (PEDECOR) from 2014 to 2018. Logistic regression and Receiver Operating Characteristics (ROC) curves were used to calculate the area under the curve (AUC) to evaluate association of mortality with the scores. Of the 655 cases, 289 (44.1%) did not survive until hospital discharge. AUCs for PIM2, PRISM III, and PELOD predicting mortality were 0.52, 0.52, and 0.51 respectively. PIM2, PRISM III, and PELOD scores are not associated with odds of mortality for pediatric patients receiving ECMO. These scores for a general pediatric ICU population should not be used for prognostication or risk stratification of a select population such as ECMO patients.
尽管常用于调整风险、疾病严重程度和死亡风险预测评分,但基于重症监护病房(ICU)入院后最初24小时的评分,尚未在儿科体外膜肺氧合(ECMO)人群中得到验证。我们旨在确定儿科死亡率指数2(PIM2)、儿科死亡风险评分III(PRISM III)和儿科逻辑器官功能障碍(PELOD)评分与接受ECMO治疗的儿科患者死亡率之间的关联。这是一项对2014年至2018年纳入儿科ECMO结果登记处(PEDECOR)的18岁及以下儿童进行的回顾性队列研究。使用逻辑回归和受试者工作特征(ROC)曲线来计算曲线下面积(AUC),以评估死亡率与评分之间的关联。在655例病例中,289例(44.1%)未存活至出院。PIM2、PRISM III和PELOD预测死亡率的AUC分别为0.52、0.52和0.51。PIM2、PRISM III和PELOD评分与接受ECMO治疗的儿科患者的死亡几率无关。这些针对普通儿科ICU人群的评分不应用于特定人群(如ECMO患者)的预后评估或风险分层。